NASDAQ
02.06.26 | 21:59
3,620 US-Dollar
-15,42 % -0,660
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.04. | Stifel reiterates Foghorn Therapeutics stock rating on AACR data | 1 | Investing.com | ||
| 22.04. | H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy | 1 | Investing.com | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.04. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | Foghorn to present preclinical cancer data at AACR meeting | 1 | Investing.com | ||
| 09.04. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 17.03. | Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress | 5 | Investing.com | ||
| 12.03. | Foghorn Therapeutics: Jefferies bekräftigt "Buy"-Rating im Vorfeld von Pipeline-Daten | 2 | Investing.com Deutsch | ||
| 12.03. | Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data | 2 | Investing.com | ||
| 12.03. | Stifel reiterates Foghorn Therapeutics stock rating at buy | 2 | Investing.com | ||
| 11.03. | Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M | 1 | Seeking Alpha | ||
| 11.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook | 218 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics appoints Ryan Maynard as CFO | 1 | Seeking Alpha | ||
| 23.02. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer | 200 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Jefferies stuft Foghorn Therapeutics mit "Buy" ein und sieht erhebliches Potenzial | 2 | Investing.com Deutsch | ||
| 17.02. | Jefferies initiates Foghorn Therapeutics stock with buy rating | 13 | Investing.com | ||
| 13.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | 270 | GlobeNewswire (Europe) | WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 258,08 | -23,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,480 | -2,46 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | -0,74 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| COGENT BIOSCIENCES | 32,760 | -6,29 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,705 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,690 | 0,00 % | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results... ► Artikel lesen | |
| DISC MEDICINE | 68,00 | -5,52 % | Disc Medicine launches expanded access program for bitopertin | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,615 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| MINERALYS THERAPEUTICS | 28,850 | -7,26 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection ... | - Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease - - In participants... ► Artikel lesen | |
| CG ONCOLOGY | 55,47 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report |
FOGHORN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,660 (-15,42 %) liegt der Kurs bei 3,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.